Skip to main content
Kent Academic Repository

Items where Author, Editor or other role is "Garrett, Michelle"

Group by: Creator's name | Item Type | Date | No Grouping
Jump to: Article | Thesis
Number of items: 49.

Article

Paul, Alexandra. R, Falsaperna, Mario, Lavender, Helen, Garrett, Michelle D., Serpell, Christopher J. (2023) Selection of optimised ligands by fluorescence-activated bead sorting. Chemical Science, 14 (35). pp. 9517-9525. ISSN 2041-6520. E-ISSN 2041-6539. (doi:10.1039/d3sc03581f) (KAR id:102640)
Format: PDF

Boles, Jessica E., Bennett, C., Baker, J., Hilton, Kira L.F., Kotak, H. A., Clark, Ewan R., Long, Y, White, Lisa J., Lai, H. Y., Hind, C. K., and others. (2022) Establishing the selective phospholipid membrane coordination, permeation and lysis properties for a series of ‘druggable’ supramolecular self-associating antimicrobial amphiphiles. Chemical Science, (33). pp. 9761-9773. ISSN 2041-6520. (doi:10.1039/D2SC02630A) (KAR id:96217)
Format: PDF Format: PDF

Appukutti, Nadeema, de Vries, Alex H, Gudeangadi, Prashant G., Claringbold, Bini, Garrett, Michelle D., Reithofer, Michael R, Serpell, Christopher J. (2022) Sequence-complementarity dependent co-assembly of phosphodiester-linked aromatic donor-acceptor trimers. Chemical communications (Cambridge, England), . ISSN 1364-548X. (doi:10.1039/d2cc00239f) (KAR id:97661)
Format: PDF

Hilton, Kira L.F., Manwani, Chandni, Boles, Jessica E., White, Lisa J., Ozturk, Sena, Garrett, Michelle D., Hiscock, Jennifer R. (2021) The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patients. Chemical Science, 12 . pp. 13273-13282. ISSN 2041-6520. (doi:10.1039/D1SC03597E) (KAR id:90289)
Format: PDF Format: XML Word Processing Document (DOCX)

Dora, Nova Olympia, Blackburn, Edith, Boles, Jessica E., Williams, George T., White, Lisa J., Turner, Scarlett, Hothersall, Trevor, Askwith, Trevor, Doolan, Jack, Mulvihill, Daniel P., and others. (2021) Supramolecular self-associating amphiphiles (SSAs) as nanoscale enhancers of cisplatin anticancer activity. RSC Advances, 11 . pp. 14213-14217. ISSN 2046-2069. (doi:10.1039/D1RA02281D) (KAR id:87520)
Format: PDF Format: PDF

Ahmad, Bilal, Friar, Emily P., Vohra, Muhammad Sufyan, Garrett, Michelle D., Serpell, Christopher J., Fong, Isabel Lim, Wong, Eng Hwa (2020) Mechanisms of action for the anti-obesogenic activities of phytochemicals. Phytochemistry, 180 . Article Number 112513. ISSN 0031-9422. (doi:10.1016/j.phytochem.2020.112513) (KAR id:84469)
Format: PDF Format: XML Word Processing Document (DOCX)

McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S., Garces, Alvaro H. Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, and others. (2020) First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, . ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-20-0700) (KAR id:82812)
Format: PDF

Pal, Akos, Asad, Yasmin, Ruddle, Ruth, Henley, Alan T., Swales, Karen, Decordova, Shaun, Eccles, Suzanne A ., Collins, Ian, Garrett, Michelle D., De Bono, Johann, and others. (2020) Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics, 16 (4). ISSN 1573-3882. (doi:10.1007/s11306-020-01676-0) (KAR id:80866)
Format: PDF

Rogers, Rebecca F, Walton, Mike I., Cherry, Daniel L, Collins, Ian, Clarke, Paul A, Garrett, Michelle D., Workman, Paul (2020) CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. Cancer Research, . ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-19-1372) (KAR id:80536)
Format: PDF

Fenton, Tim R., Garrett, Michelle D., Michaelis, Martin, Wass, Mark N. (2018) Meeting Abstracts of the BACR conference: response and resistance in cancer therapy. Cancer Drug Resistance, 1 . pp. 266-302. E-ISSN 2578-532X. (doi:10.20517/cdr.2018.18) (KAR id:73043)
Format: PDF

Fenton, Tim R., Garrett, Michelle D., Wass, Mark N., Michaelis, Martin (2018) What really matters - response and resistance in cancer therapy. Cancer Drug Resistance, 2018 (1). pp. 200-203. ISSN 2578-532X. (doi:10.20517/cdr.2018.19) (KAR id:71006)
Format: PDF

Banerji, Udai, Dean, Emma J., Pérez-Fidalgo, J. Alejandro, Batist, Gerald, Bedard, Philippe L., You, Benoit, Westin, Shannon N., Kabos, Peter, Garrett, Michelle D., Tall, Mathew, and others. (2018) A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clinical Cancer Research, 24 (9). pp. 2050-2059. ISSN 1078-0432. E-ISSN 1557-3265. (doi:10.1158/1078-0432.CCR-17-2260) (KAR id:63859)
Format: PDF Format: PDF

Whittaker, Steven R., Barlow, Clare, Martin, Mathew P., Mancusi, Caterina, Wagner, Steve, Self, Annette, Barrie, Elaine, te Poele, Robert, Sharp, Swee, Brown, Nathan, and others. (2018) Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Molecular Oncology, 12 . pp. 287-304. ISSN 1574-7891. E-ISSN 1878-0261. (doi:10.1002/1878-0261.12148) (KAR id:64152)
Format: PDF

Moreno, Lucas, Caron, Hubert, Geoerger, Birgit, Eggert, Angelika, Schleiermacher, Gudrun, Brock, Penelope, Valteau-Couanet, Dominique, Chesler, Louis, Schulte, Johannes H, De Preter, Katleen, and others. (2017) Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12 (8). pp. 801-811. ISSN 1746-0441. E-ISSN 1746-045X. (doi:10.1080/17460441.2017.1340269) (KAR id:63861)
Format: PDF Format: PDF

Saintas, Emily, Abrahams, Liam, Ahmed, Gulshan T, Ajakaiye, Anu-Oluwa M, AlHumaidi, Abdulaziz S H A M, Ashmore-Harris, Candice, Clark, Iain, Dura, Usha K, Fixmer, Carine N, Ike-Morris, Chinedu, and others. (2017) Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. PLoS ONE, 12 (2). Article Number 172140. ISSN 1932-6203. (doi:10.1371/journal.pone.0172140) (KAR id:60364)
Format: PDF

Sumbayev, Vadim V., Silva, Isabel Gonçalves, Blackburn, Jennifer, Gibbs, Bernhard F, Yasinska, Inna M., Garrett, Michelle D., Tonevitsky, Alexandre G., Ushkaryov, Yuri (2016) Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells. Oncotarget, 7 . pp. 45575-45583. E-ISSN 1949-2553. (doi:10.18632/oncotarget.10039) (KAR id:58343)
Format: PDF

Osborne, James D., Matthews, Thomas P., McHardy, Tatiana, Proisy, Nicolas, Cheung, Kwai-Ming J., Lainchbury, Michael, Brown, Nathan, Walton, Michael I., Eve, Paul D., Boxall, Katherine J., and others. (2016) Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). Journal of Medicinal Chemistry, 59 (11). pp. 5221-5237. ISSN 0022-2623. (doi:10.1021/acs.jmedchem.5b01938) (KAR id:58552)
Format: PDF

Smith, Jennifer R., Moreno, Lucas, Heaton, Simon P., Chesler, Louis, Pearson, Andrew D.J., Garrett, Michelle D. (2016) Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology, 10 (4). pp. 538-552. ISSN 1574-7891. (doi:10.1016/j.molonc.2015.11.005) (KAR id:55391)
Format: PDF

Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Boxall, Kathy J., Box, Gary, Tall, Matthew, Swales, Karen, and others. (2015) The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. Oncotarget, 7 (3). pp. 2329-2342. E-ISSN 1949-2553. (doi:10.18632/oncotarget.4919) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:54924)

Sadok, Amine, McCarthy, Afshan, Caldwell, John, Collins, Ian, Garrett, Michelle D., Yeo, Maggie, Hooper, Steven, Sahai, Erik, Kuemper, Sandra, Mardakheh, Faraz K., and others. (2015) Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis. Cancer Research, 75 (11). pp. 2272-2284. ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-14-2156) (KAR id:50204)
Format: PDF

Yap, Timothy A., Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P., Olmos, David, Baird, Richard, Delgado, Liliana, and others. (2014) Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 20 (22). pp. 5672-5685. ISSN 1078-0432. E-ISSN 1557-3265. (doi:10.1158/1078-0432.CCR-14-0868) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:54928)

Garrett, Michelle D. (2014) JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene, 33 . pp. 1148-1157. (doi:10.1038/onc.2013.46) (KAR id:86611)
Format: PDF

Touchefeu, Yann, Khan, Aadil A., Borst, Gerben, Zaidi, Shane H., McLaughlin, Martin, Roulstone, Victoria, Mansfield, David, Kyula, Joan, Pencavel, Tim, Karapanagiotou, Eleni M., and others. (2013) Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. Radiotherapy and Oncology, 108 (1). pp. 24-31. ISSN 0167-8140. (doi:10.1016/j.radonc.2013.05.036) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58555)

Wang, Qiming Jane, Silva-Santisteban, M. Cris, Westwood, Isaac M., Boxall, Kathy, Brown, Nathan, Peacock, Sam, McAndrew, Craig, Barrie, Elaine, Richards, Meirion, Mirza, Amin, and others. (2013) Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. PLoS ONE, 8 (6). e65689. ISSN 1932-6203. (doi:10.1371/journal.pone.0065689) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58556)

Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, and others. (2012) Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors. Journal of Medicinal Chemistry, 55 (22). pp. 10229-10240. ISSN 0022-2623. (doi:10.1021/jm3012933) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58560)

Walton, Mike I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Hallsworth, Albert, Smith, Elizabeth L., Boxall, Kathy J., Lainchbury, Michael, and others. (2012) CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research, 18 (20). pp. 5650-5661. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-12-1322) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58558)

Borst, Gerben R., McLaughlin, Martin, Kyula, Joan N., Neijenhuis, Sari, Khan, Aadil, Good, James, Zaidi, Shane, Powell, Ned G., Meier, Pascal, Collins, Ian, and others. (2012) Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106. International Journal of Radiation Oncology Biology Physics, 85 (4). pp. 1110-1118. ISSN 0360-3016. (doi:10.1016/j.ijrobp.2012.08.006) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58562)

Yap, Timothy A., Walton, Mike I., Grimshaw, Kayla M., te Poele, Robert H., Eve, Paul D., Valenti, Melanie R., De Haven Brandon, Alexis K., Martins, Vanessa, Zetterlund, Anna, Heaton, Simon P., and others. (2012) AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Clinical Cancer Research, 18 (14). pp. 3912-3923. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-11-3313) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58561)

Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, Michelle D., Clarke, P. A., and others. (2012) The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics, 11 (7). pp. 1609-1617. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-11-0996) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58563)

Banerji, Udai, van Doorn, Leni, Papadatos-Pastos, Dionysis, Kristeleit, Rebecca, Debnam, Phillip, Tall, Matthew, Stewart, Adam, Raynaud, Florence, Garrett, Michelle Dawn, Toal, Martin, and others. (2012) A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research, 18 (9). pp. 2687-2694. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-11-3165) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58565)

Bernhard, Eric J., Stockwell, Simon R., Platt, Georgina, Barrie, S. Elaine, Zoumpoulidou, Georgia, te Poele, Robert H., Aherne, G. Wynne, Wilson, Stuart C., Sheldrake, Peter, McDonald, Edward, and others. (2012) Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling. PLoS ONE, 7 (1). e28568. ISSN 1932-6203. (doi:10.1371/journal.pone.0028568) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58566)

Reader, John C., Matthews, Thomas P., Klair, Suki, Cheung, Kwai-Ming J., Scanlon, Jane, Proisy, Nicolas, Addison, Glynn, Ellard, John, Piton, Nelly, Taylor, Suzanne, and others. (2011) Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing. Journal of Medicinal Chemistry, 54 (24). pp. 8328-8342. ISSN 0022-2623. (doi:10.1021/jm2007326) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58567)

Anderson, Victoria E., Walton, Michael I., Eve, Paul D., Boxall, Katherine J., Antoni, Laurent, Caldwell, John J., Aherne, Wynne, Pearl, Laurence H., Oliver, Antony W., Collins, Ian, and others. (2011) CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Research, 71 (2). pp. 463-472. ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-10-1252) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58568)

Yap, T. A., Walton, M. I., Hunter, L.-J. K., Valenti, M., de Haven Brandon, A., Eve, P. D., Ruddle, R., Heaton, S. P., Henley, A., Pickard, L., and others. (2010) Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics, 10 (2). pp. 360-371. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-10-0760) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58569)

Caldwell, John J., Welsh, Emma J., Matijssen, Cornelis, Anderson, Victoria E., Antoni, Laurent, Boxall, Kathy, Urban, Frederique, Hayes, Angela, Raynaud, Florence I., Rigoreau, Laurent J. M., and others. (2010) Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2. Journal of Medicinal Chemistry, 54 (2). pp. 580-590. ISSN 0022-2623. (doi:10.1021/jm101150b) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58571)

Matthews, Thomas P., McHardy, Tatiana, Klair, Suki, Boxall, Kathy, Fisher, Martin, Cherry, Michael, Allen, Charlotte E., Addison, Glynn J., Ellard, John, Aherne, G. Wynne, and others. (2010) Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorganic & Medicinal Chemistry Letters, 20 (14). pp. 4045-4049. ISSN 0960-894X. (doi:10.1016/j.bmcl.2010.05.096) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58572)

Grimshaw, K. M., Hunter, L.-J. K., Yap, T. A., Heaton, S. P., Walton, M. I., Woodhead, S. J., Fazal, L., Reule, M., Davies, T. G., Seavers, L. C., and others. (2010) AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics, 9 (5). pp. 1100-1110. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-09-0986) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58573)

McHardy, Tatiana, Caldwell, John J., Cheung, Kwai-Ming, Hunter, Lisa J., Taylor, Kevin, Rowlands, Martin, Ruddle, Ruth, Henley, Alan, de Haven Brandon, Alexis, Valenti, Melanie, and others. (2010) Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry, 53 (5). pp. 2239-2249. ISSN 0022-2623. (doi:10.1021/jm901788j) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58574)

Walton, M. I., Eve, P. D., Hayes, A., Valenti, M., De Haven Brandon, A., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., and others. (2010) The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics, 9 (1). pp. 89-100. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-09-0938) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58575)

Hilton, Stephen, Naud, Sebastien, Caldwell, John J., Boxall, Kathy, Burns, Samantha, Anderson, Victoria E., Antoni, Laurent, Allen, Charlotte E., Pearl, Laurence H., Oliver, Antony W., and others. (2009) Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorganic & Medicinal Chemistry, 18 (2). pp. 707-718. ISSN 0968-0896. (doi:10.1016/j.bmc.2009.11.058) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58576)

Thesis

Paul, Alexandra Rosie (2022) A Novel Strategy for the Synthetic Selection of Enhanced Therapeutic Aptamers. Doctor of Philosophy (PhD) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.97439) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:97439)
Format: PDF

Cherry, Daniel (2022) Investigating Resistance to Checkpoint Kinase 1 Inhibitors in Triple Negative Breast Cancer. Doctor of Philosophy (PhD) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.95339) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:95339)
Format: PDF

Grimsley, Helen Elizabeth (2021) Investigating mechanisms of acquired drug resistance in Triple Negative Breast Cancer. Doctor of Philosophy (PhD) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.88062) (KAR id:88062)
Format: PDF

Breeds, Nathan (2020) Investigating mechanisms of acquired resistance to AT13148, an AGC kinase inhibitor. Doctor of Philosophy (PhD) thesis, University of Kent,. (KAR id:82198)
Format: PDF

Dora, Nova Olympia (2020) Development of novel antimicrobials as potential anticancer treatments. Master of Science by Research (MScRes) thesis, University of Kent,. (KAR id:81198)
Format: PDF

Jakubowski, Jasmine Marie (2019) Investigating mechanisms of acquired resistance to the AKT inhibitor capivasertib (AZD5363). Doctor of Philosophy (PhD) thesis, University of Kent,. (KAR id:80960)
Format: PDF

Tappenden, Natasha Anne (2019) Investigation mechanisms of acquired resistance to CHK1 inhibitors in the human ovarian cancer cell line PEO1. Master of Science by Research (MScRes) thesis, University of Kent,. (KAR id:79565)
Format: PDF

Page, Jonathan James (2017) Understanding insulin signalling and its role in regulating ageing in C elegans using pharmacological and genetic approaches. Master of Science by Research (MScRes) thesis, University of Kent,. (KAR id:66732)
Format: PDF Format: HTML

Doyle, Kevin (2016) Investigating the effects of novel AKT inhibitors on the insulin/IGF-1 like signalling pathway in C. elegans. Master of Research (MRes) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.59976) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:59976)
Format: PDF

This list was generated on Thu Apr 18 19:40:28 2024 BST.